Literature DB >> 15468604

Technology evaluation: ABT-510, Abbott.

Johan R Westphal1.   

Abstract

ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15468604

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  10 in total

Review 1.  The thrombospondins.

Authors:  Josephine C Adams; Jack Lawler
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-10-01       Impact factor: 10.005

Review 2.  Integration of pro- and anti-angiogenic signals by endothelial cells.

Authors:  Shideh Kazerounian; Jack Lawler
Journal:  J Cell Commun Signal       Date:  2017-12-20       Impact factor: 5.782

Review 3.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.

Authors:  Jie Ma; David J Waxman
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

Review 4.  Enhancing cardiovascular dynamics by inhibition of thrombospondin-1/CD47 signaling.

Authors:  Jeff S Isenberg; William A Frazier; Murali C Krishna; David A Wink; David D Roberts
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

5.  Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells.

Authors:  Jeff S Isenberg; Christine Yu; David D Roberts
Journal:  Biochem Pharmacol       Date:  2007-11-01       Impact factor: 5.858

Review 6.  Thrombospondin-based antiangiogenic therapy.

Authors:  Xuefeng Zhang; Jack Lawler
Journal:  Microvasc Res       Date:  2007-05-06       Impact factor: 3.514

Review 7.  Thrombospondins in cancer.

Authors:  S Kazerounian; K O Yee; J Lawler
Journal:  Cell Mol Life Sci       Date:  2008-03       Impact factor: 9.261

8.  Capillary sprout endothelial cells exhibit a CD36 low phenotype: regulation by shear stress and vascular endothelial growth factor-induced mechanism for attenuating anti-proliferative thrombospondin-1 signaling.

Authors:  Christopher R Anderson; Nicole E Hastings; Brett R Blackman; Richard J Price
Journal:  Am J Pathol       Date:  2008-09-04       Impact factor: 4.307

Review 9.  Thrombospondins: A Role in Cardiovascular Disease.

Authors:  Dimitry A Chistiakov; Alexandra A Melnichenko; Veronika A Myasoedova; Andrey V Grechko; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2017-07-17       Impact factor: 5.923

Review 10.  Novel endogenous angiogenesis inhibitors and their therapeutic potential.

Authors:  Nithya Rao; Yu Fei Lee; Ruowen Ge
Journal:  Acta Pharmacol Sin       Date:  2015-09-14       Impact factor: 6.150
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.